Summary
A series of hydroxamates, which are not metalloprotease inhibitors, have been found to be selectively toxic to a range of transformed and human tumour cells without killing normal cells (fibroblasts, melanocytes) at the same concentrations. Within 24 h of treatment, drug action is characterized by morphological reversion of tumour cells to a more normal phenotype (dendritic morphology), and rapid and reversible acetylation of histone H4 in both tumour and normal cells. Two hydroxamates inhibited growth of xenografts of human melanoma cells in nude mice; resistance did not develop in vivo or in vitro. A third hydroxamate, trichostatin A, was active in vitro but became inactivated and had no anti-tumour activity in vivo. Development of dendritic morphology was found to be dependent upon phosphatase activity, RNA and protein synthesis. Proliferating hybrid clones of sensitive and resistant cells remained sensitive to ABHA, indicating a dominant-negative mechanism of sensitivity. Histone H4 hyperacetylation suggests that these agents act at the chromatin level. This work may lead to new drugs that are potent, and selective anti-tumour agents with low toxicity to normal cells.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Andreeff, M., Stone, R., Michaeli, J., Young, C. W., Tong, W. P., Sogoloff, H., Ervin, T., Kufe, D., Rifkind, R. A. & Marks, P. A. (1992). Hexamethylene bis acetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiating agent. Blood 80: 2604–2609.
Beere, H. M. & Hickman, J. A. (1993). Differentiation: a suitable strategy for cancer chemotherapy? Anticancer Drug Des 8: 299–322.
Boulikas, T. (1994). A compilation and classification of DNA binding sites for protein transcription factors from vertebrates. Crit Rev Euk Gene Exp 4: 117–321.
Breslow, R., Jursic, B., Yan, Z. F., Friedman, E., Leng, L., Ngo, L., Rifkind, R. A. & Marks, P. A. (1991). Potent cytodifferentiating agents related to hexamethylenebisacetamide. Proc Natl Acad Sci USA 88: 5542–5546.
Chen, T. R. (1977). In situ detection of Mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. Exp Cell Res 104: 255–262.
Hoshikawa, Y., Kwon, H. J., Yoshida, M., Horinouchi, S. & Beppu, T. (1994). Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines. Exp Cell Res 214: 189–197.
Kijima, M., Yoshida, M., Sugita, K., Horinouchi, S. & Beppu, T. (1993). Trapoxin is an irreversible inhibitor of mammalian histone deacetylase. J Biol Chem 268: 22429–22435.
Kiyokawa, H., Richon, V. M., Rifkind, R. A. & Marks, P. A. (1994). Suppression of cyclin-dependent kinase 4 during induced differentiation of erythroleukemia cells. Mol Cell Biol 14: 7195–7203.
Marks, P. A., Richon, V. M., Kiyokawa, H. & Rifkind, R. A. (1994). Inducing differentiation of transformed cells with hybrid polar compounds: a cell-cycle dependent process. Proc Natl Acad Sci USA 91: 10251–10254.
Maynard, K. & Parsons, P. G. (1986). Cross sensitivity to methylating agents, hydroxyurea and methotrexate in human tumour cells of the Mer phenotype. Cancer Res 46: 5009–5013.
McBain, J. A., Eastman, A., Nobel, C. S. & Mueller, G. C. (1997). Apoptotic death in adenocarcinoma cell lines induced by butyrate and other histone deacetylase inhibitors. Biochem Pharmacol 53: 1357–1368.
Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytoxicity assays. J Immunol Methods 65: 55–63.
Musk, P., Clark, J. M., Thompson, D., Dunn, I. S., Christopherson, R. I., Szabados, E., Rose, S. E. & Parsons, P. G. (1996). Purine deoxynucleoside metabolism in human melanoma cells with a high spontaneous mutation rate. Mutat Res 350: 229–238.
Nakamura, T., Okuyama, S., Okamoto, S., Nakajima, T., Sekiya, S. & Oda, K. (1995). Down-regulation of the cyclin A promoter in differentiating human embryonal carcinoma cells is mediated by depletion of ATF-1 and ATF-2 in the complex at the ATF/CRE site. Exp Cell Res 216: 422–430.
Palitti, F., Carotti, D., Busiello, V., Bendicenti, A., Strom, R. & DiGirolamo, M. (1993). DNA hypomethylation and differentiation in Friend leukemia cell variants. Biochim Biophys Acta 1216: 50–54.
Parsons, P. G., Favier, D., McEwan, M., Takahashi, H., Jimbow, K. & Ito, S. (1991). Action of cysteaminyl phenols on human melanoma cells in vivo and in vitro: 4-S-cysteaminylphenol binds protein disulphide isomerase. Melanoma Res 1: 97–104.
Parsons, P. G., Hansen, C., Fairlie, D. P., West, M. L., Danoy, P., Sturm, R. A., Dunn, I. S., Pedley, J. & Ablett, E. (1997). Tumor selectivity and transcriptional activation by azelaic bishydroxamic acid in human melanocytic cells. Biochem Pharmacol 53: 1719–1724.
Perrine, S. P., Olivieri, N. F., Faller, D. V., Vichinsky, E. P., Dover, G. J. & Ginder, G. D. (1994). Butyrate derivatives. New agents for stimulating fetal globin production in the beta-globin disorders. Am J Ped Hematol Oncol 16: 67–71.
Rasmussen, H. S. & McCann, P. P. (1997). Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimatstat and maximastat. Pharmacol Therap 75: 69–75.
Richon, V. M. & Ventaperez, G. (1996). Changes in E2F DNA-binding activity during induced erythroid differentiation. Cell Growth Diff 7: 31–42.
Richon, V. M., Webb, Y., Merger, R., Sheppard, T., Jursic, B., Ngo, L., Civoli, F., Breslow, R., Rifkind, R. A. & Monks, P. A. (1996). Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci USA 93: 5705–5708.
Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A. & Marks, P. A. (1998). A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 95: 3003–3007.
Rifkind, R. A., Richon, V. M. & Monks, P. A. (1996). Induced differentiation, the cell cycle and the treatment of cancer. Pharmacol Therap 69: 97–102.
Rowinsky, E. K., Conley, B. A., Jones, R. J., Spivak, J. L., Auerbach, M. & Donehower, R. C. (1992). HMBA in myelodysplastic syndrome: effect of five-day exposure to maximal therapeutic concentrations. Leukemia 6: 526–534.
Saito, S., Crissman, H. A., Nishijiima, M., Kagabu, T., Nishiya, I. & Cram, L. S. (1991). Flow cytometric and biochemical analysis of dose-dependent effects of sodium butyrate on human endometrial adenocarcinoma cells. Cytometry 12: 757–764.
Schroy, P. C., Rustgi, A. K., Ikonomu, E., Liu, X. P., Polito, J., Andry, C. & O’Keane, J. C. (1994). Growth and intestinal differentiation are independently regulated in HT29 colon cancer cells. J Cell Physiol 161: 111–123.
Stoker, A. & Dutta, R. (1998). Protein tyrosine phosphatases and neural development. BioEssays 20: 463–472.
Thyberg, J., Hultgardh-Nilsson, A. & Kallin, B. (1995). Inhibitors of ADP-ribosylation suppress phenotypic modulation and proliferation of smooth muscle cells cultured from rat aorta. Differentiation 59: 243–252.
Wang, X., Hafezparast, M. & Masters, J. R. (1996). Genetic basis of drug sensitivity in human testis tumour cells. Int J Cancer 65: 426–431.
Wolffe, A. P. & Pruss, D. (1996). Targetting chromatin disruption: transcription regulators that acetylate histones. Cell 84: 817–819.
Yoshida, M., Horinouchi, S. & Beppu, T. (1995). Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. BioEssays 17: 423–430.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Qiu, L., Kelso, M., Hansen, C. et al. Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br J Cancer 80, 1252–1258 (1999). https://doi.org/10.1038/sj.bjc.6690493
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bjc.6690493
Keywords
This article is cited by
-
Improved therapeutic effect on malignant glioma with adenoviral suicide gene therapy combined with temozolomide
Gene Therapy (2013)
-
Transcriptional regulation of human osteopontin promoter by histone deacetylase inhibitor, trichostatin A in cervical cancer cells
Molecular Cancer (2010)
-
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
Clinical Epigenetics (2010)
-
Targeting the epigenome: effects of epigenetic treatment strategies on genomic stability in healthy human cells
Clinical Epigenetics (2010)
-
Drug Insight: histone deacetylase inhibitors—development of the new targeted anticancer agent suberoylanilide hydroxamic acid
Nature Clinical Practice Oncology (2005)
